The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.

[1]  Wasim Abdool Karim,et al.  Rapid replacement of the Beta variant by the Delta variant in South Africa , 2021, medRxiv.

[2]  A. Ryo,et al.  Neutralizing efficacy of vaccines against the SARS-CoV-2 Mu variant , 2021, medRxiv.

[3]  Jorge Fernández,et al.  Neutralization of alpha, gamma, and D614G SARS‐CoV‐2 variants by CoronaVac vaccine‐induced antibodies , 2021, Journal of medical virology.

[4]  L. Solari,et al.  Genomic analysis reveals a rapid spread and predominance of lambda (C.37) SARS‐COV‐2 lineage in Peru despite circulation of variants of concern , 2021, Journal of medical virology.

[5]  O. Pybus,et al.  Viral infection and Transmission in a large well-traced outbreak caused by the Delta SARS-CoV-2 variant , 2021, medRxiv.

[6]  P. Romero,et al.  The Emergence of Sars-CoV-2 Variant Lambda (C.37) in South America , 2021, medRxiv.

[7]  Mehrdad Mohammadi,et al.  The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines , 2021, The Brazilian Journal of Infectious Diseases.

[8]  O. Mor,et al.  Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  P. Dormitzer,et al.  BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants , 2021, The New England journal of medicine.

[10]  D. Swerdlow,et al.  Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data , 2021, The Lancet.

[11]  E. Mendelson,et al.  Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 , 2021, The New England journal of medicine.

[12]  D. Stuart,et al.  Antibody evasion by the P.1 strain of SARS-CoV-2 , 2021, Cell.

[13]  M. Hernán,et al.  BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting , 2021, The New England journal of medicine.

[14]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[15]  Philip R. O. Payne,et al.  The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment , 2020, J. Am. Medical Informatics Assoc..

[16]  Trevor Bedford,et al.  Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.